Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

“Securing this patent strengthens our intellectual property portfolio, continuing progress on naronapride’s global clinical development,” said Dr. Peter Milner, M.D., FACC, Chairman and CEO of ...

Consider adenosine A 2A receptor antagonists, for example, which are being evaluated as an adjuvant therapy to L-dopa or D 2 receptor agonists for Parkinson's disease, based on the evidence of ...

New Delhi: IQVIA has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...